The novel p53 isoform "delta p53" is a misfolded protein and does not bind the p21 promoter site

Protein Science

Volumn 17, Issue 10, 2008, Pages 1671-1678

  García Alai, Maria M ^a   Tidow, Henning ^a   Natan, Eviatar ^a   Townsley, Fiona M ^a   Veprintsev, Dmitry B ^a   Fersht, Alan R ^a  

^a MRC CENTRE FOR PROTEIN ENGINEERING   (United Kingdom)

Author keywords

DNA binding domains; Dominant negative mutation; Protein structure folding; Structure function studies

Indexed keywords

ISOPROTEIN; MESSENGER RNA; PROTEIN DELTA P53; PROTEIN FLP53; PROTEIN P21; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; DNA BINDING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; RNA EDITING;

ALTERNATIVE SPLICING; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN ISOFORMS; PROTEIN STRUCTURE, SECONDARY; SEQUENCE DELETION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 52949134486     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.036996.108     Document Type: Article

References (39)

1. Alonso, L.G., García-Alai, M.M., Smal, C., Centeno, J.M., Iacono, R., Castano, E., Gualfetti, P., and de Prat-Gay, G. 2004. The HPV16 E7 viral oncoprotein self-assembles into defined spherical oligomers. Biochemistry 43: 3310-3317.
2. Ang, H.C., Joerger, A.C., Mayer, S., and Fersht, A.R. 2006. Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J. Biol. Chem. 281: 21934-21941.
3. Baumbusch, L.O., Myhre, S., Langerod, A., Bergamaschi, A., Geisler, S.B., Lonning, P.E., Deppert, W., Dornreiter, I., and Borresen-Dale, A.L. 2006. Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters. Mol. Cancer 5: 47. doi: 10.1186/1476-4598-5-47.
4. Bourdon, J.C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D.P., Saville, M.K., and Lane, D.P. 2005. p53 isoforms can regulate p53 transcriptional activity. Genes & Dev. 19: 2122-2137.
5. Bullock, A.N., Henckel, J., and Fersht, A.R. 2000. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy. Oncogene 19: 1245-1256.
6. Canadillas, J.M., Tidow, H., Freund, S.M., Rutherford, T.J., Ang, H.C., and Fersht, A.R. 2006. Solution structure of p53 core domain: Structural basis for its instability. Proc. Natl. Acad. Sci. 103: 2109-2114.
7. Chan, W.M. and Poon, R.Y. 2007. The p53 isoform Δp53 lacks intrinsic transcriptional activity and reveals the critical role of nuclear import in dominant-negative activity. Cancer Res. 67: 1959-1969.
8. Cho, Y., Gorina, S., Jeffrey, P.D., and Pavletich, N.P. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265: 346-355.
9. Clore, G.M., Ernst, J., Clubb, R., Omichinski, J.G., Kennedy, W.M., Sakaguchi, K., Appella, E., and Gronenborn, A.M. 1995. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat. Struct. Biol. 2: 321-333.
10. Deyoung, M.P. and Ellisen, L.W. 2007. p63 and p73 in human cancer: Defining the network. Oncogene 26: 5169-5183.
11. García-Alai, M.M., Dantur, K.I., Smal, C., Pietrasanta, L., and de Prat-Gay, G. 2007. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines. Biochemistry 46: 341-349.
12. Guinier, A. 1939. La diffraction des rayons X aux tres petits angles: Application a l'etude de phenomenes ultramicroscopiques. Ann. Phys. 12: 161-237.
13. Hainaut, P. and Hollstein, M. 2000. p53 and human cancer: The first ten thousand mutations. Adv. Cancer Res. 77: 81-137.
14. Harms, K.L. and Chen, X. 2005. The C terminus of p53 family proteins is a cell fate determinant. Mol. Cell. Biol. 25: 2014-2030.
15. Ho, W.C., Fitzgerald, M.X., and Marmorstein, R. 2006. Structure of the p53 core domain dimer bound to DNA. J. Biol. Chem. 281: 20494-20502.
16. Hu, A. and Fu, X.D. 2007. Splicing oncogenes. Nat. Struct. Mol. Biol. 14: 174-175.
17. Hunt, J.B., Neece, S.H., and Ginsburg, A. 1985. The use of 4-(2-pyridylazo) resorcinol in studies of zinc release from Escherichia coli aspartate transcarbamoylase. Anal. Biochem. 146: 150-157.
18. Joerger, A.C. and Fersht, A.R. 2007. Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene 26: 2226-2242.
19. Joerger, A.C., Ang, H.C., Veprintsev, D.B., Blair, C.M., and Fersht, A.R. 2005. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J. Biol. Chem. 280: 16030-16037.
20. Joerger, A.C., Ang, H.C., and Fersht, A.R. 2006. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl. Acad. Sci. 103: 15056-15061.
21. Karni, R., de Stanchina, E., Lowe, S.W., Sinha, R., Mu, D., and Krainer, A.R. 2007. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14: 185-193.
22. Konarev, P.V., Volkov, V.V., Sokolova, A.V., Koch, M.H.J., and Svergun, D.I. 2003. PRIMUS: A Windows PC-based system for small-angle scattering data analysis. J. Appl. Crystallogr. 36: 1277-1282.
23. Kriventseva, E.V., Koch, I., Apweiler, R., Vingron, M., Bork, P., Gelfand, M.S., and Sunyaev, S. 2003. Increase of functional diversity by alternative splicing. Trends Genet. 19: 124-128.
24. Lakowicz, J.R. 1999. Principles of fluorescence spectroscopy, 2d ed. Kluwer Academic/Plenum Publishers, New York.
25. Lee, W., Harvey, T.S., Yin, Y., Yau, P., Litchfield, D., and Arrowsmith, C.H. 1994. Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol. 1: 877-890.
26. Mateu, M.G. and Fersht, A.R. 1998. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J. 17: 2748-2758.
27. Mateu, M.G. and Fersht, A.R. 1999. Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization. Proc. Natl. Acad. Sci. 96: 3595-3599.
28. Murray-Zmijewski, F., Lane, D.P., and Bourdon, J.C. 2006. p53/p63/p73 isoforms: An orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 13: 962-972.
29. Neira, J.L., Vazquez, E., and Fersht, A.R. 2000. Stability and folding of the protein complexes of barnase. Eur. J. Biochem. 267: 2859-2870.
30. Nilsen, T.W. 1994. RNA-RNA interactions in the spliceosome: Unraveling the ties that bind. Cell 78: 1-4.
31. Prives, C. and Manfredi, J.J. 2005. The continuing saga of p53 - more sleepless nights ahead. Mol. Cell 19: 719-721.
32. Roessle, M.W., Klaering, R., Ristau, U., Robrahn, B., Jahn, D., Gehrmann, T., Konarev, P., Round, A., Fiedler, S., Hermes, C., et al. 2007. Upgrade of the small-angle X-ray scattering beamline X33 at the European Molecular Biology Laboratory, Hamburg. J. Appl. Crystallogr. 40: S190-S194.
33. Rohaly, G., Chemnitz, J., Dehde, S., Nunez, A.M., Heukeshoven, J., Deppert, W., and Dornreiter, I. 2005. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 122: 21-32.
34. Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., and Rotter, V. 1990. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10: 6565-6577.
35. Svergun, D.I. 1992. Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J. Appl. Crystallogr. 25: 495-503.
36. Tidow, H., Melero, R., Mylonas, E., Freund, S.M., Grossmann, J.G., Carazo, J.M., Svergun, D.I., Valle, M., and Fersht, A.R. 2007. Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc. Natl. Acad. Sci. 104: 12324-12329.
37. Veprintsev, D.B., Freund, S.M., Andreeva, A., Rutledge, S.E., Tidow, H., Canadillas, J.M., Blair, C.M., and Fersht, A.R. 2006. Core domain interactions in full-length p53 in solution. Proc. Natl. Acad. Sci. 103: 2115-2119.
38. Weinberg, R.L., Veprintsev, D.B., and Fersht, A.R. 2004. Cooperative binding of tetrameric p53 to DNA. J. Mol. Biol. 341: 1145-1159.
39. Wells, M., Tidow, H., Rutherford, T.J., Markwick, P., Jensen, M.R., Mylonas, E., Svergun, D.I., Blackledge, M., and Fersht, A.R. 2008. Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc. Natl. Acad. Sci. 105: 5762-5767.